资源描述：
《关于胃癌分子靶向治疗的临床研究》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。
1、1.AStudyofAvastin(Bevacizumab)inCombinationWithXeloda(Capecitabine)andCisplatinasFirst-LineTherapyforAdvancedGastricCancer（recruitingparticipants）PurposeThis2armstudywillcomparetheefficacyandsafetyofAvastinversusplacebo,incombinationwithXelodaandcisplatin,inpatie
2、ntswhohavereceivednopriortreatmentforadvancedormetastaticgastriccancer.PatientswillberandomizedtoreceiveeitherAvastin7.5mg/kgivorplaceboiv,incombinationwithXeloda1000mg/m2pobidondays1-14ofeach3weekcycle,andcisplatin80mg/m2every3weeks.Theanticipatedtimeonstudytrea
3、tmentisuntildiseaseprogression,andthetargetsamplesizeis100-500individuals.ConditionInterventionPhaseGastricCancerDrug:bevacizumab[Avastin]Drug:capecitabine[Xeloda]Drug:cisplatinDrug:PlaceboPhaseIIIStudyType:InterventionalStudyDesign:Treatment,Randomized,DoubleBli
4、nd(Subject,Investigator),ParallelAssignment,Safety/EfficacyStudyOfficialTitle:ADouble-blind,Randomised,Multicenter,PhaseIIIStudyofBevacizumabinCombinationWithCapecitabineandCisplatinVersusPlaceboinCombinationWithCapecitabineandCisplatin,asFirst-lineTherapyinChine
5、sePatientsWithAdvancedGastricCancer.2.Pre-OperativeChemotherapyPlusBevacizumabWithEarlySalvageTherapyBasedonPETAssessmentofResponseinPatientsWithLocallyAdvancedButResectableGastricandGEJAdenocarcinomaThisstudyiscurrentlyrecruitingparticipants.VerifiedbyMemorialSl
6、oan-KetteringCancerCenter,July2009FirstReceived:August15,2008 LastUpdated:July1,2009 HistoryofChangesSponsorsandCollaborators:MemorialSloan-KetteringCancerCenterGenentechInformationprovidedby:MemorialSloan-KetteringCancerCenterClinicalTrials.govIdentifier:NCT0073
7、7438 PurposeThisstudyisbeingdonetofindouthoweffectiveanewtreatmentstrategyisonyourcancer.Inthisstrategy,theresponseyourtumorhastothefirstcycleoftherapywillhelpselectthenexttreatments.Wealsowillfindouttheeffects,bothgoodand/orbad,adrugcalledbevacizumabhasonyouandy
8、ourtumorwhengivenwithchemotherapy.ConditionInterventionPhaseEsophagealCancerGastricCancerDrug:epirubicin,cisplatin,capecitabine,bevacizumab,docetaxelandirinote
